[144] PTC Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 notice for PTC Therapeutics, Inc. (PTCT): An individual proposes to sell 22,664 shares of common stock, with an aggregate market value of $1,382,537.32, on or about 09/11/2025 through Fidelity Brokerage Services (NASDAQ). The filing shows the shares were acquired as an option granted on 01/07/2022 and payment is expected in cash upon sale. The issuer has 79,438,094 shares outstanding, and the filing also discloses a recent sale by Mark Boulding of 2,813 shares on 08/15/2025 for gross proceeds of $136,646.45. The filer attests they are not aware of undisclosed material adverse information.

Positive

• Transparent compliance: The filer submitted a Rule 144 notice detailing acquisition date, source (option grant), broker, and intended sale date.
• Use of established broker: Sale is planned through Fidelity Brokerage Services on NASDAQ, indicating orderly market execution.

Negative

• Insider selling: An insider intends to sell 22,664 shares, which may be perceived negatively by some investors despite its small size.
• Recent insider sale: Mark Boulding sold 2,813 shares on 08/15/2025 for $136,646.45, indicating prior insider liquidity activity.

Insights

Securities Analyst

TL;DR: Insiders plan a modest sale of option-held shares via a retail broker; transaction size is small relative to outstanding shares.

The filing discloses a proposed sale of 22,664 common shares acquired by option, to be executed through Fidelity on NASDAQ with an aggregate market value of $1.38 million. Given the issuer's stated 79.44 million shares outstanding, the position represents a de minimis percentage of the float. The prior small sale by Mark Boulding provides recent precedent of insider liquidity activity. This notice is routine disclosure under Rule 144 and signals planned monetization of vested option holdings rather than an extraordinary corporate event.

Corporate Governance Specialist

TL;DR: Routine insider sale filing; key governance control is the attestation of no undisclosed material information.

The form includes the standard representation that the seller is unaware of any undisclosed material adverse information, and it indicates the securities were acquired by option grant. Execution through a major broker and an explicit sale date supports orderly disposition under Rule 144. From a governance perspective, the filing meets disclosure obligations but does highlight insider liquidity; stakeholders may note timing relative to any pending public announcements.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	22664	1382537.32	79438094	09/11/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/11/2025	Option Granted - 01/07/2022	Issuer			22664	09/11/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Mark Boulding 500 Warren Corporate Center Drive Warren NJ 07059	Common	08/15/2025	2813	136646.45

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for PTCT disclose?

The notice discloses a proposed sale of 22,664 common shares with an aggregate market value of $1,382,537.32, to be sold on or about 09/11/2025 through Fidelity on NASDAQ.

How were the shares to be sold acquired?

The shares were acquired via an option granted on 01/07/2022 and are to be paid for in cash at sale.

How large is the proposed sale relative to PTCT's outstanding shares?

The filing reports 79,438,094 shares outstanding; the proposed 22,664 shares represent a very small fraction of that total.

Did the filing disclose any recent insider sales?

Yes. The filing shows Mark Boulding sold 2,813 shares on 08/15/2025 for gross proceeds of $136,646.45.

Does the filer state there is undisclosed material information?

The filer attests by signing the notice that they do not know of any material adverse information about the issuer that has not been publicly disclosed.